ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...

"Our customers all over the world consistently tell us how our FreeStyle Libre technology has made an enormous, positive impact on their health and quality of life – they spend less time worrying and ...

- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms 1 to alert users when their glucose is high or low without scanning - Now for ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...